VG | Jotup

Think Silicon to Showcase its Latest Ultra-Low-Power 3D Graphics and AI in One IP Architecture at Embedded World 2024

Retrieved on:

星期三, 四月 3, 2024

SOC, GPU, Sport, Rotation, Artificial intelligence of things, Memory, Library, Embedded, SAN, MCU, 3D, AI, Linux, Silicon, Architecture, Animation, VG, Lighting, SDK, Collection, GPGPU, TensorFlow, Video game

ATHENS, Greece and SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Think Silicon, the leading provider of ultra-low-power GPU and AI IP for embedded systems, will showcase its latest graphics and AI solutions for edge computing devices in Hall 4, Booth 476 at Embedded World 2024 taking place in Nuremberg, Germany from April 9-11.

Key Points:

ATHENS, Greece and SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Think Silicon, the leading provider of ultra-low-power GPU and AI IP for embedded systems, will showcase its latest graphics and AI solutions for edge computing devices in Hall 4, Booth 476 at Embedded World 2024 taking place in Nuremberg, Germany from April 9-11.
Think Silicon’s NEOX® | GA100 is a GPGPU solution for the MCU market based on RISC-V, offering the unique combination of performing both 3D graphics and ΑΙ in one IP architecture.
The processor can be programmed using graphics and AI libraries independently or together.
Think Silicon’s experts will be available for meetings and demonstrations of the NEMA® and NEOX® product series at Embedded World.

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Retrieved on:

星期四, 三月 28, 2024

Phase 3 clinical endpoints include changes after 4D-710 treatment in ppFEV1, quality-of-life (Cystic Fibrosis Questionnaire Revised Respiratory Domain, CFQ-R-RD) and frequency of pulmonary exacerbations.

Key Points:

Phase 3 clinical endpoints include changes after 4D-710 treatment in ppFEV1, quality-of-life (Cystic Fibrosis Questionnaire Revised Respiratory Domain, CFQ-R-RD) and frequency of pulmonary exacerbations.
The Company anticipates initiation of technology transfer to a commercial contract development and manufacturing organization (CDMO) in H1 2025.
Our goal is to initiate Phase 3 development in H2 2025 with 4D-710 suspension GMP process clinical trial material.
We look forward to sharing interim clinical data from the AEROW Phase 1/2 clinical trial at the ECFS conference in June 2024.”

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on:

星期二, 三月 19, 2024

Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points:

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
ET to review its financial and operating results and to provide corporate and clinical updates.

White Gold Corp. Announces Upcoming Conferences

Retrieved on:

星期二, 三月 12, 2024

Consultant, Conference, Interest, Q&A, Agnico Eagle, Investment, Arsenic, Inference, Gold, Arc, MRE, FRA, Anomaly, Betty, OTCQX, RAB, VG, White Gold, Kinross Gold, Tellurium, Soil

The Company’s significant gold resources and other discoveries continue to demonstrate the expansiveness of gold mineralization on its extensive and underexplored land package in the emerging White Gold District, Yukon, Canada, with its exploration supported by strategic partners including Agnico Eagle Mines Limited and Kinross Gold Corporation.

Key Points:

The Company’s significant gold resources and other discoveries continue to demonstrate the expansiveness of gold mineralization on its extensive and underexplored land package in the emerging White Gold District, Yukon, Canada, with its exploration supported by strategic partners including Agnico Eagle Mines Limited and Kinross Gold Corporation.
In 2023, the Company successfully increased the size of its gold resources and published an updated Mineral Resource Estimate (“MRE”) (1) for its flagship White Gold Project significantly updating the MRE to include 16.11 million tonnes of Indicated Resources averaging 2.23 grams per tonne gold for 1.153 million ounces of gold and 18.99 million tonnes of Inferred Resources averaging 1.54 grams per tonne gold for 942,400 million ounces of gold, representing an increase of Inferred Resources by 41%.
The updated MRE also includes a maiden resource estimate for the Ryan’s Surprise deposit, which included an Inferred Resource of 227,700 ounces of gold averaging 1.97 grams per tonne gold.
The Company plans to attend multiple conferences in 2024, in addition to the conferences already attended, including the conference outlined below.

Venture Guides Launches Sales Academy to Accelerate Portfolio Company Growth

Retrieved on:

星期二, 四月 2, 2024

Data Management, Security, Technology, Software, Networks, Internet, Partnership, Interview, Guide, SALES, Curriculum, VG, Marketing, Development

Venture Guides , an early stage venture capital firm focused on team-based investing and guiding, today announced the launch of Venture Guides’ Sales Academy for Leadership, Excellence, and Success (VG SALES) designed to accelerate sales for its portfolio companies with trained and motivated sales professionals, ready to join fast growing tech startups.

Key Points:

Venture Guides , an early stage venture capital firm focused on team-based investing and guiding, today announced the launch of Venture Guides’ Sales Academy for Leadership, Excellence, and Success (VG SALES) designed to accelerate sales for its portfolio companies with trained and motivated sales professionals, ready to join fast growing tech startups.
With a steadfast commitment to fostering the success of its portfolio companies, Venture Guides recognizes the critical role of sales execution in early, sustainable growth.
"At Venture Guides, we understand the challenges start-ups face when hiring, training, and launching a sales team," said Ben Nye, Co-founder and Managing Partner of Venture Guides.
Our sales academy is one of the many ways we help our portfolio companies; leveraging decades of proven, hands-on experience as operators and company builders.”
“The VG SALES program underscores Venture Guides' commitment to providing unparalleled support and strategic guidance to its portfolio companies,” said Naj Husain, Co-founder and CEO, Elastio .

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Retrieved on:

星期四, 二月 29, 2024

Central nervous system, Index, Adolescence, FDA, MTD, Food, MECP2, IDMC, Rett syndrome, Safety, CNS, Patient, VG, Mutation, AAV, Ageing, Pharmaceutical industry

DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced updates to its TSHA-102 program in clinical evaluation for the treatment of Rett syndrome. The Independent Data Monitoring Committee (IDMC) approved the Company’s request to proceed to dose escalation in the REVEAL Phase 1/2 adolescent and adult trial, enabling earlier advancement to the high dose cohort of 1x1015 total vg. The IDMC also approved the dosing of the second patient in cohort one (low dose) of 5.7x1014 total vg in the REVEAL Phase 1/2 pediatric trial. The decisions follow IDMC review of available clinical data from the patients dosed with TSHA-102. The Company also announced the expansion of its ongoing REVEAL Phase 1/2 adolescent and adult trial in Canada into the United States (U.S.) following submission of the adolescent and adult trial protocol to the U.S. Food and Drug Administration (FDA).

Key Points:

The decisions follow IDMC review of available clinical data from the patients dosed with TSHA-102.
The trial is taking place in Canada and the U.S. TSHA-102 is administered as a single lumbar intrathecal injection.
Update on available clinical data from completed cohort one of 5.7x1014 total vg expected in the first quarter of 2024.
Initial safety and efficacy data from cohort two (high dose, n=3) of 1x1015 total vg expected in the second half of 2024.

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

Retrieved on:

星期四, 二月 29, 2024

We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.

Key Points:

We currently expect cash and cash equivalents to be sufficient to fund operations into the first half of 2027.
R&D Expenses: Research and development expenses were $97.1 million for 2023, as compared to $80.3 million for 2022.
G&A Expenses: General and administrative expenses were $36.5 million for 2023, as compared to $32.9 million for 2022.
Net Loss: Net loss was $100.8 million for 2023, as compared to net loss of $107.5 million for 2022.

White Gold Corp. Discovers 1 km Long Gold-In-Soil Anomaly 9 km Northwest of Its VG Deposit, White Gold District, Yukon, Canada

Retrieved on:

星期四, 二月 22, 2024

Soil, QV, AEM, IEX, Anomaly, Interest, TSX, Kinross Gold, FRA, Overalls, Conference, KGC, Figure, Arsenic, Gold, PDAC, White Gold, NNW, Orientation, OTCQX, VG, Magnetism, Tellurium, Agnico Eagle, Rare-earth element

The new soil geochemical anomaly appears to be similar in character to the VG deposit and the Golden Saddle deposit which form part of the Company’s flagship White Gold Project.

Key Points:

The new soil geochemical anomaly appears to be similar in character to the VG deposit and the Golden Saddle deposit which form part of the Company’s flagship White Gold Project.
The strike length, continuity, and similarities of the soil anomaly relative to the surface geochemical signatures of our Golden Saddle and VG deposits represents an exciting new target.
The soil sampling program consisted of approximately 200 samples collected at 50 m sample spacings on 100 m-spaced survey lines.
The principal gold anomaly is localized at this fault intersection, associated with a semi-circular magnetic high approximately 1 km in diameter.

Eaton introduces three new power take-off applications and hydraulic control valves at Work Truck Show

Retrieved on:

星期三, 二月 28, 2024

(Photo: Business Wire)

Key Points:

(Photo: Business Wire)
APSCO, an Eaton distribution partner, offers a complementary, versatile product line with a large installed base.
These valve offerings will help Eaton distributors with replacement parts and can also be used for new installs.
Bezares USA is a global manufacturer of PTOs, hydraulic pumps, fittings, tanks, valves and other related mobile power hydraulic components.
Eaton has a distribution agreement with Bezares USA and APSCO to serve as a distributor for mobile power hydraulic portfolio and hydraulic control valves, respectively.

Indigenous Prosperity Foundation Announces Inaugural Board of Directors

Retrieved on:

星期三, 二月 21, 2024

IPF, Senior, Woman, Economic development, DMZ, Entrepreneurship, Capacity building, Culture, Empowerment, Government, Chairperson, Organization, First Nations, Executive, Public policy, VG, Internet, Partnership, Management

OTTAWA, ON, Feb. 21, 2024 /CNW/ - The Indigenous Prosperity Foundation (IPF) proudly unveils its inaugural Board of Directors, a crucial milestone in advancing Indigenous empowerment and economic prosperity.

Key Points:

OTTAWA, ON, Feb. 21, 2024 /CNW/ - The Indigenous Prosperity Foundation (IPF) proudly unveils its inaugural Board of Directors, a crucial milestone in advancing Indigenous empowerment and economic prosperity.
Bobbie Racette: As the inaugural Chair of IPF's Board of Directors, Bobbie Racette brings visionary leadership and extensive entrepreneurial experience.
"As Chair of the Board, my vision for the Indigenous Prosperity Foundation is to build a future on our own terms, where Indigenous entrepreneurs lead the way to prosperity for our communities," said Bobbie Racette, IPF Board Chair.
"It is with great pride and excitement that we welcome the inaugural Board of Directors of Indigenous Prosperity Foundation," said Shannin Metatawabin, CEO of NACCA.